A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

This is a Phase 1, open-label, multicenter study of KBP-5209 administered orally once daily
(QD) in 28-day treatment cycles to adult patients with advanced solid tumors which have
progressed despite standard therapy or for which no standard therapy exists. This study is
designed to determine the MTD or RP2D and to characterize the safety, tolerability, and PK
profile of KBP-5209.

Inclusion Criteria:

- Age 18 years or older;

- Patients with histologically or cytologically confirmed, advanced solid tumors which
have progressed despite standard therapy or for whom no standard therapy exists.

- Patients must have at least one measurable or non-measurable lesion (dose escalation
only) as defined by RECIST v1.1

- Eastern Cooperative Oncology Group performance score 0 to 2;

Exclusion Criteria:

- Patients with symptomatic CNS metastases;

- Patients who have a known history of hepatitis C or chronic active hepatitis B or a
known diagnosis of HIV

- Any significant ophthalmologic abnormality

- Patients who have any severe and/or uncontrolled medical conditions

- Significant gastrointestinal abnormalities,

- Patients who have impaired cardiac function or clinically significant cardiac
diseases,

- Chemotherapy, biologic therapy, immunotherapy, radiotherapy or investigational agents
within 5 half-lives or within 4 weeks (whichever is longer) prior to administration
of the first dose of study drug on Day 1 or have not recovered from the side effects
of such therapy;

- Treatment with third generation EGFR inhibitors

- Major surgery/surgical therapy for any cause within 4 weeks of Screening;